ReviewJournal of inflammation research2021
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19.
Review in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Interleukin-17 as a spatiotemporal bridge from acute to chronic inflammation: Novel insights from computational modeling.WIREs mechanisms of diseasePooled it
- Network Pharmacology and Animal Experimental Validation on the Therapeutic Mechanisms ofClinical, cosmetic and investigational dermatology · 2026Article
- A Global Study of Skin and Subcutaneous Diseases Among Individuals Under 20 Years of Age.Clinical, cosmetic and investigational dermatology · 2026Article
- Bridging worlds: a narrative review of IL-17 at the crossroads of inflammation and thrombosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Inflamed Skin, Burdened Heart: A Multidisciplinary Perspective on Atopic Dermatitis and Cardiovascular Health.Clinical, cosmetic and investigational dermatology · 2025Review
- Burden, Trends, Risk Factors, and Forecast of Ischemic Heart Disease, Rheumatic Heart Disease, and Atrial Fibrillation and Flutter From 1990 to 2040: A Comparative Analysis of China, the United States, and Europe Based on the Global Burden of Disease Study and the Potential Impact of the COVID-19 Pandemic.Vascular health and risk management · 2025Article
- An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications.Virulence · 2023Review
- Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.MedComm · 2023Review
- Article
- A Peek into Pandora's Box: COVID-19 and Neurodegeneration.Brain sciences · 2022Review
- Interleukin-17A influences the vulnerability rather than the size of established atherosclerotic plaques in apolipoprotein E-deficient mice.Open life sciences · 2022Article
- Protective effects of Jing-Si-herbal-tea in inflammatory cytokines-induced cell injury on normal human lung fibroblastTzu chi medical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has posed a serious problem for drug anti-viral efficacy in combatting the cytokine storm triggered by SARS-CoV-2. From dermato-epidemiological studies conducted on psoriatic and other rheumatological patients, IL-17 inhibitors seem to attenuate or even prevent the cytokine storm and thus ICU referral. Furthermore, both in-vivo and in-vitro experiments suggest that IL-17 plays a key role in SARS-CoV-2 infection progression. Due to this evidence, we decided to summarize the literature findings on IL-17 inhibitors and COVID-19, maintaining psoriasis as the referral disease to better understand the extent of drug effects on the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.